Exactech Announces Successful First Surgeries Using InterSep Calcium Sulfate Bone Void Filler

Exactech, a developer and producer of bone and joint restoration products for extremities, hip, and knee, announced today the successful first surgery using its new InterSep calcium sulfate bone void filler.

Exactech notes: One of the newest additions to Exactech’s infection-related solutions, InterSep is a 100% synthetic calcium sulfate bone void filler that is engineered to fully resorb and replace bone during the healing process. Made in the United States, InterSep may be used in a variety of bone and joint replacement surgeries, including infected bone sites. It provides surgeons flexibility with its bead and paste options.

Orthopedic surgeons Mark Brandon, M.D., of Richmond University Medical Center in Staten Island, NY, and Timothy van de Leur, M.D., of The Orthopaedic Institute, Ocala, Fla., performed the first cases using InterSep and report excellent results.

As a revision total joint specialist, van de Leur is pleased that Exactech continues to support surgeons with new and relevant infection solutions. “InterSep was fast and easy to use with its flexible putty or bead options. InterSep will help to reassure me when patients present greater risk or are already dealing with infection.”

InterSep is manufactured by Pacific Bioceramics and distributed exclusively by Exactech. It is currently available at select hospitals and surgery centers throughout the U.S. with plans for full launch during the second half of the year.

SourceExactech
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Led by researchers at NYU Grossman School of Medicine, the study results add to evidence that neighboring brain regions, the inferior frontal gyrus and the motor cortex, play an important role in such planning before words are said aloud. Both are part of the folded top layers of the brain, or cerebral cortex, which has long been known to control the muscle (motor) movements in the throat and mouth needed to produce speech. Less clear until now was how closely these regions determine the mix of sounds and words people want to say aloud, the authors report.
PolarisAR describes STELLAR Knee as a mixed-reality surgical navigation platform that guides TKA procedures by displaying measured and computed data overlaid directly in a 3D environment. The mixed-reality system acts as a spatial computer, creating continuous data exchange between the surgeon and the software to help enhance surgical decision-making while simplifying operating room workflow.
This February, the first enrolled patient underwent open surgical aortic arch reconstruction at the University of Pennsylvania, Presbyterian Medical Center, Philadelphia, PA.  During the surgery, the Duett Vascular Graft System was successfully deployed to connect the native left common carotid artery to the surgical graft.
"Our ultra low insertion loss Athermal AWG Multiplexers along with temperature-hardened low-drift AAWG specifically designed for the industrial temperature applications will be marketed aggressively through partnership companies in the East Asia and EU regions after its success in the North America," says Dr. Donald Yu, CMO of POINTek, who runs global marketing operations from Los Angeles, California.
AUX-001 is an innovative, once-daily, extended-release formulation of Nicorandil. For decades, immediate-release, twice daily Nicorandil has been a cornerstone treatment for chronic angina symptoms outside the US, distinguished by its dual mechanism of action that targets both the micro- and macrovascular coronary artery flow bed, and providing sustained angina symptom relief without the common issue of tachyphylaxis seen with other anti-anginal vasodilators like long-acting nitrates. AUX-001 offers efficacy comparable to conventional anti-anginal medications such as beta-blockers, calcium channel blockers, and long-acting nitrates while also potentially enhancing control of the underlying coronary disease and reducing angina related hospitalizations.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version